Xeris Biopharma Holdings (XERS) said Friday it now expects 2024 revenue of $203 million, compared with its prior guidance of between $198 million and $202 million.
Analysts polled by FactSet expect $199.7 million.
The company said it expects Q4 revenue of $60 million.
Analysts surveyed by FactSet expect $56.7 million.
Price: 3.38, Change: +0.02, Percent Change: +0.60
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.